Nobel Hunting for Acquisitions?

posted in Nobel Biocare, Implant Industry News

« Suture Lost Exposing the Implant: What to Do? | Bone Resorption Data on Astra Implants »

Print This Post

Swiss dental implant maker Nobel Biocare (NOBN.VX) expects an improvement in business in the second half, the company’s chief executive was quoted as saying in a newspaper interview, boosting the company’s shares.

“The second half of the year should already be better,” Nobel Biocare CEO Domenico Scala told Swiss weekly newspaper Handelszeitung, according to an interview released on Tuesday, a day ahead of the paper’s publication.

The company has shocked investors with a series of profit warnings in recent months, missing targets as customers cut spending due to economic uncertainty.

Scala said the company’s current forecast would remain valid after the second quarter if the overall economy did not deteriorate further.

Nobel Biocare shares have lost around 36 percent so far this year, sparking speculation that the world’s largest maker of dental implants could be taken over.

“We have the financial as well as the strategic resources to form our future alone,” Scala told the newspaper when asked about the market talk. The company was eyeing acquisitions itself, Scala said: “It is clear that growth will also happen through acquisitions.”


Nobel Biocare was looking for smaller targets in the range of 50 to 100 million Swiss francs ($48.45 to $96.90 million) in the field of ceramics or software, Scala said.

(Source: Reuters, Reporting by Sven Egenter; Editing by Will Waterman and David Holmes)

Have an Implant Question?
>>Ask Us Now!

Free Daily Email Alert Click Here>>

Get OsseoNews.com Comments delivered daily! Click Here to subscribe.

One Response to “ Nobel Hunting for Acquisitions? ”

  • Sebastian Fernandez November 19th, 2008

    I believe it will be very difficult to get Nobel Biocare new investors if it continues with this policy of excessive spending, it is clear that the profits of the company are good, but when comparing costs, as we are losing balance, for the sample of the subsidiary Nobel Biocare Colombia has one of the most extravagant spending and one of the most deficient of all governments Nobel Biocare, but that does not seem to matter to the CEO as the manager continues to spend and squander hands full.

    That’s why it will be difficult to get investors sr Domenico Scala

Leave a Comment

Note: Please refrain from ad hominem attacks, and promotional comments. Outside links are not permitted in comments. Though we require an email to route questionable comments to our editors, we will NEVER publish your email or use it for any other purpose. Thank you for your understanding.


Note: At times your comment may not appear on the website immediately, because it has been sent to our editors for approval. Once approved, we will publish the comment. There is NO need to resubmit your comment, if it does not appear on the website immediately.